Erlotinib-Induced Cardiomyopathy in a Patient with Metastatic Non-Small Cell Lung Cancer
Author:
Affiliation:
1. Department of Cardiology, Faculty of Medicine, University of Tsukuba
Publisher
International Heart Journal (Japanese Heart Journal)
Subject
Cardiology and Cardiovascular Medicine,General Medicine
Link
https://www.jstage.jst.go.jp/article/ihj/62/5/62_21-130/_pdf
Reference10 articles.
1. 1. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011; 12: 735-42.
2. 2. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012; 13: 239-46.
3. 3. Reck M, Van Zandwijk N, Gridelli C, et al. Erlotinib in advanced non-small cell lung cancer: Efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study. J Thorac Oncol 2010; 5: 1616-22.
4. 4. Kus T, Aktas G, Sevinc A, Kalender ME, Camci C. Could erlotinib treatment lead to acute cardiovascular events in patients with lung adenocarcinoma after chemotherapy failure? Onco Targets Ther 2015; 8: 1341-3.
5. 5. Ding S, Long F, Jiang S. Acute myocardial infarction following erlotinib treatment for NSCLC: A case report. Oncol Lett 2016; 11: 4240-4.
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. EGFR inhibition leads to enhanced desmosome assembly and cardiomyocyte cohesion via ROCK activation;JCI Insight;2023-03-22
2. A systematic review of epidermal growth factor receptor tyrosine kinase inhibitor-induced heart failure and its management;The Egyptian Journal of Internal Medicine;2022-12
3. EGFR inhibition led ROCK activation enhances desmosome assembly and cohesion in cardiomyocytes;2022-04-28
4. Erlotinib/gefitinib;Reactions Weekly;2021-11
5. Cardiovascular Complications by EGFR Tyrosine Kinase Inhibitors in Patients with Lung Cancer;International Heart Journal;2021-09-29
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3